We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$385M
AUM Growth
-$36.8M
Cap. Flow
-$9.14M
Cap. Flow %
-2.37%
Top 10 Hldgs %
72.83%
Holding
43
New
5
Increased
16
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$20.3M
2
INSM icon
Insmed
INSM
+$7.93M
3
VERV
Verve Therapeutics
VERV
+$4.58M
4
NTLA icon
Intellia Therapeutics
NTLA
+$3.84M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.51M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$18.4M
2
CYTK icon
Cytokinetics
CYTK
+$9.36M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.63M
4
YMAB
Y-mAbs Therapeutics
YMAB
+$6.4M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$2.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
26
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.32M 0.6%
319,671
– –
PHAT icon
27
Phathom Pharmaceuticals
PHAT
$743M
$2.2M 0.57%
195,942
+2,616
+1% +$27K
KDNY
28
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.1M 0.54%
+80,000
New +$1.77M
PRAX icon
29
Praxis Precision Medicines
PRAX
$9.63B
$1.45M 0.38%
+40,667
New +$1.27M
ONCR
30
DELISTED
Oncorus, Inc.
ONCR
$601K 0.16%
2,377,031
– –
TECX
31
Tectonic Therapeutic
TECX
$696M
$462K 0.12%
53,993
– –
BDTX icon
32
Black Diamond Therapeutics
BDTX
$128M
$261K 0.07%
144,888
-95,000
-40% -$171K
INZY
33
DELISTED
Inozyme Pharma
INZY
$242K 0.06%
230,500
-430,644
-65% -$753K
ADCT icon
34
ADC Therapeutics
ADCT
$146M
– –
-334,384
Closed -$1.61M
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-412,363
Closed -$2.07M
BCRX icon
36
BioCryst Pharmaceuticals
BCRX
$2.51B
– –
-605,663
Closed -$7.63M
CYTK icon
37
Cytokinetics
CYTK
$10B
– –
-193,205
Closed -$9.36M
EPIX
38
DELISTED
ESSA Pharma
EPIX
– –
-405,700
Closed -$738K
EWTX icon
39
Edgewise Therapeutics
EWTX
$4.64B
– –
-304,027
Closed -$2.99M
MIRM icon
40
Mirum Pharmaceuticals
MIRM
$5.94B
– –
-97,322
Closed -$2.04M
MRUS
41
DELISTED
Merus
MRUS
– –
-918,310
Closed -$18.4M
VSTM icon
42
Verastem
VSTM
$654M
– –
-270,388
Closed -$2.76M
YMAB
43
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-443,702
Closed -$6.4M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2022 Portfolio in Review

As of Q4 2022, MPM BioImpact held 43 positions worth $385M, down 8.7% from $422M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

MPM BioImpact's Q4 2022 filing shows 5 new, 16 increased, 4 reduced and 10 closed positions. Its largest new stake was uniQure: 939,966 shares worth $21.3M. The largest sale was Merus, an estimated $18.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q4 2022 buy was uniQure: 939,966 shares worth $21.3M.
  • MPM BioImpact added most to Verve Therapeutics in Q4 2022, an estimated $4.58M increase.
  • MPM BioImpact's biggest Q4 2022 reduction was Madrigal Pharmaceuticals, cutting an estimated $1.76M.
  • MPM BioImpact fully exited Merus in Q4 2022, selling an estimated $18.4M.
  • MPM BioImpact's ten largest holdings make up 73% of its $385M portfolio in Q4 2022.
  • MPM BioImpact opened 5 new positions and closed 10 in Q4 2022.
  • MPM BioImpact's portfolio value fell 8.7% quarter-over-quarter to $385M.

Based on MPM BioImpact's 13F filing for Q4 2022, filed 14 Feb 2023.